Analyzing Evaxion A/S (NASDAQ:EVAX) and Aspyra (OTCMKTS:APYI)

Aspyra (OTCMKTS:APYI) and Evaxion A/S (NASDAQ:EVAX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Aspyra and Evaxion A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspyra	0	0	0	0	0.00
Evaxion A/S	1	0	4	1	2.83

Evaxion A/S has a consensus target price of $11.75, indicating a potential upside of 271.84%. Given Evaxion A/S’s stronger consensus rating and higher possible upside, analysts clearly believe Evaxion A/S is more favorable than Aspyra.

Risk and Volatility

Aspyra has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500.

Profitability

This table compares Aspyra and Evaxion A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aspyra	N/A	N/A	N/A
Evaxion A/S	N/A	-68.82%	-24.12%

Valuation & Earnings

This table compares Aspyra and Evaxion A/S”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspyra	N/A	N/A	N/A	N/A	N/A
Evaxion A/S	$3.34 million	7.89	-$10.57 million	($0.39)	-8.10

Aspyra has higher earnings, but lower revenue than Evaxion A/S.

Institutional & Insider Ownership

11.0% of Evaxion A/S shares are owned by institutional investors. 23.9% of Aspyra shares are owned by insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Evaxion A/S beats Aspyra on 7 of the 10 factors compared between the two stocks.

About Aspyra

Aspyra Inc. provides health care products and services for the laboratory and imaging marketplaces. It offers engineered workflow solutions that include software, interfaces, hardware, and professional services to various markets comprising specialty labs, reference labs, clinics, hospitals, imaging centers, and orthopedic practices. The company was formerly known as Creative Computer Applications Inc. and changed its name to Aspyra Inc. in November 2005. Aspyra Inc. was founded in 1978 and is headquartered in Jacksonville, Florida.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.